Form 4: Incyte CFO Christiana Stamoulis Reports Significant Equity Grants and Tax-Related Share Dispositions

Incyte Corporation's EVP & Chief Financial Officer, Christiana Stamoulis, reported the acquisition of substantial restricted stock units, performance shares, and stock options, alongside tax-related dispositions of common stock.

Summary

• Christiana Stamoulis, EVP & Chief Financial Officer of Incyte Corp, reported transactions involving company stock.
• On July 14, 2025, 1,407 shares of common stock were disposed of at $69.98 per share to satisfy tax withholding obligations.
• On July 15, 2025, an additional 1,445 shares of common stock were disposed of at $68.25 per share for tax withholding purposes.
• On July 15, 2025, 11,107 restricted stock units (RSUs) were awarded at a price of $0, which will vest 25% annually over four years and settle one-for-one for common stock.
• On July 15, 2025, 27,769 performance shares were awarded at a price of $0, with potential to receive up to 200% of one common share based on relative total shareholder return (TSR) over a three-year period starting January 1, 2025, vesting on July 15, 2028.
• On July 15, 2025, 24,998 employee stock options were granted at an exercise price of $68.25, expiring on July 14, 2035, with 25% vesting after one year and the remainder monthly over three years.
• Following these transactions, Christiana Stamoulis beneficially owns 125,759 shares of common stock directly, including 64,006 unvested shares from previous awards.
• Additionally, 27,769 performance shares and 24,998 employee stock options are beneficially owned directly.

Sentiment

Score: 8

Explanation: The sentiment is positive due to significant new equity grants to a key executive, aligning her interests with long-term company performance. The share dispositions are routine tax withholdings and do not indicate negative sentiment.

Positives

• Significant equity grants (11,107 RSUs, 27,769 performance shares, 24,998 stock options) indicate continued long-term incentive alignment with shareholder interests.
• Performance shares are tied to the company's relative Total Shareholder Return (TSR) over three years, incentivizing strong performance against peers.
• The grants increase the executive's overall beneficial ownership and long-term stake in the company's success.

Negatives

• Disposition of 2,852 shares of common stock (1,407 + 1,445) occurred to cover tax withholding obligations, which is a standard practice and not indicative of a negative outlook.

Future Outlook

The document details future vesting schedules for restricted stock units (25% annually over four years), performance shares (vesting on July 15, 2028, based on relative TSR over a three-year period starting January 1, 2025), and employee stock options (25% vesting after one year, remainder monthly over three years, expiring July 14, 2035). These grants align executive incentives with long-term company performance.

Industry Context

This Form 4 filing reflects standard executive compensation practices within the biotechnology and pharmaceutical industry, where equity grants like RSUs, performance shares, and stock options are common tools to align executive incentives with long-term shareholder value creation and retain key talent. The use of performance-based awards, such as those tied to relative Total Shareholder Return (TSR), is a prevalent mechanism to encourage competitive performance within the sector.

Comparison to Industry Standards

• The compensation structure, involving a mix of restricted stock units, performance shares, and stock options, is consistent with typical executive compensation packages observed in large-cap biotechnology and pharmaceutical companies.
• For instance, companies like Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) frequently utilize similar long-term incentive vehicles to reward executives based on company performance and stock appreciation.
• The specific vesting schedules and performance metrics (e.g., relative TSR) are tailored to Incyte's strategic objectives but broadly align with best practices for executive retention and motivation in the highly competitive life sciences industry.

Stakeholder Impact

• Shareholders: The equity grants align the CFO's incentives with shareholder value creation, potentially leading to improved long-term performance.
• Employees: The compensation structure may serve as a benchmark or motivator for other employees, particularly those with equity compensation.

Next Steps

• Restricted Stock Units (RSUs) will vest 25% annually over four years from July 15, 2025.
• Performance shares will be earned based on Incyte's relative Total Shareholder Return (TSR) over a three-year period beginning January 1, 2025, and will vest on July 15, 2028.
• Employee stock options will become exercisable in 37 installments, with the first 25% vesting after one year from July 15, 2025, and the remainder vesting monthly over three years.

Key Dates

Keywords

Incyte Corp, INCY, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Performance Shares, Executive Compensation, Equity Grant, Tax Withholding, Christiana Stamoulis, CFO